BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
The 10 Most Compelling Forerunners in Innovation - 25 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 3More people are addicted to marijuana, but fewer of them are seeking help, experts say
- 4Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- 5Fundamental Home Machines: An Easy to understand Determination Guide
- Make your choice for the bird that catches your heart!
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- Vote In favor of Your Favored Pet Consideration Administration
- Photos: Presidential turkey pardons — a look back
- Manual for Vegetarian Protein Powder
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Improving as a Cook: Culinary Experiences in the Kitchen
